NARCOMS Registry: Understanding Multiple Sclerosis
The NARCOMS Registry is an ongoing project that collects health information from a large group of people with multiple sclerosis (MS) or clinically isolated syndrome (CIS). This registry helps researchers understand how MS progresses and how different treatments affect people over time. There isn't a specific drug or intervention being tested; instead, the study observes real-world disease and treatment patterns. You can join if you are at least 18 years old and have been diagnosed with MS or CIS. The main goal is to track how your disease changes over many years, up to 15 years. The study is currently active and looking for participants.
- Study design
- This is an observational study, meaning it collects information without testing a specific intervention. It aims to enroll 50,000 participants.
- What's involved
- You will complete an enrollment survey online or by mail, and then update your information twice a year. Each update takes less than 20 minutes.
- Compensation
- There is no cost to participate.
- Follow-up
- Your disease progression will be followed for up to 15 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NARCOMS Registry: A Multiple Sclerosis Registry
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Robert J. Fox, M.D. · STUDY_DIRECTOR · Mellen Center for MS / Cleveland Clinic
- Amber Salter, Ph.D. · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center
- Gary R Cutter, Ph.D. · STUDY_DIRECTOR · University of Alabama at Birmingham
- Ruth Ann Marrie, M.D., Ph.D. · STUDY_DIRECTOR · Dalhousie University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Disease progression over time of follow upup to 15 years
Disease Progression measured using the Patient Determined Disease Steps